CHF Solutions (CHFS) Cut to Sell at Zacks Investment Research

CHF Solutions (NASDAQ:CHFS) was downgraded by Zacks Investment Research from a “hold” rating to a “sell” rating in a research report issued to clients and investors on Thursday, Zacks.com reports.

According to Zacks, “CHF Solutions, Inc. is a medical device company which focused on commercializing the Aquadex FlexFlow (R) System. Its commercial product Aquadex system, is indicated for temporary ultrafiltration treatment of patients with fluid overload who have failed diuretic therapy and extended ultrafiltration treatment of patients with fluid overload who have failed diuretic therapy and require hospitalization. CHF Solutions Inc., formerly known as Sunshine Heart Inc., is headquartered in Minneapolis. “

Separately, ValuEngine downgraded shares of CHF Solutions from a “buy” rating to a “hold” rating in a report on Monday, February 4th.

Shares of CHFS traded up $0.01 on Thursday, reaching $3.42. The company’s stock had a trading volume of 51,900 shares, compared to its average volume of 157,448. The company has a current ratio of 5.86, a quick ratio of 5.12 and a debt-to-equity ratio of 0.03. The company has a market cap of $7.91 million, a price-to-earnings ratio of -0.08 and a beta of 2.65. CHF Solutions has a 12-month low of $3.15 and a 12-month high of $44.10.

CHF Solutions (NASDAQ:CHFS) last posted its quarterly earnings data on Tuesday, May 7th. The company reported ($11.47) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($1.42) by ($10.05). The business had revenue of $1.22 million during the quarter. CHF Solutions had a negative return on equity of 188.60% and a negative net margin of 336.26%. As a group, analysts predict that CHF Solutions will post -5.53 EPS for the current fiscal year.

In other news, CEO John L. Erb purchased 9,523 shares of the stock in a transaction on Tuesday, March 12th. The shares were acquired at an average price of $5.25 per share, with a total value of $49,995.75. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. 3.50% of the stock is owned by insiders.

Institutional investors have recently added to or reduced their stakes in the company. Virtu Financial LLC bought a new stake in shares of CHF Solutions during the first quarter valued at approximately $58,000. Vanguard Group Inc bought a new stake in shares of CHF Solutions during the third quarter valued at approximately $39,000. Renaissance Technologies LLC bought a new stake in shares of CHF Solutions during the first quarter valued at approximately $218,000. Finally, Perkins Capital Management Inc. bought a new stake in shares of CHF Solutions during the first quarter valued at approximately $470,000. Hedge funds and other institutional investors own 87.83% of the company’s stock.

CHF Solutions Company Profile

CHF Solutions, Inc, a medical device company, focuses on the provision of solutions for patients suffering from fluid overload. The company's commercial product is the Aquadex FlexFlow system, which is indicated for temporary ultrafiltration treatment of patients with fluid overload who have failed diuretic therapy, and extended ultrafiltration treatment of patients with fluid overload who have failed diuretic therapy and require hospitalization.

Further Reading: Reverse Stock Split

Get a free copy of the Zacks research report on CHF Solutions (CHFS)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for CHF Solutions Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CHF Solutions and related companies with MarketBeat.com's FREE daily email newsletter.